- By Jessica Wilson
Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, reflects on his testimony before the FDA Advisory Committee regarding Galleri, a multi-cancer early detection (MCED) test.
In his remarks, Dr. Puckrein highlights the potential of innovative MCED tools to complement established cancer screening methods and help identify more cancers at earlier stages. He also emphasizes the importance of ensuring that advances in cancer detection reach communities that have experienced dis
proportionate cancer burdens, health disparities, and barriers to timely diagnosis and care.
The Advisory Committee’s vote recommending approval represents an important milestone in the discussion around MCED testing and the future of cancer detection. As the FDA continues its evaluation, Dr. Puckrein underscores the need to keep patients, families, and communities at the center of conversations about innovation, access, earlier detection, and better opportunities for cancer prevention and survival.
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Jessica Wilson
- Victor Mejia
- Jessica Wilson
